📰 View Release News
View Release News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from View Release. Real-time updates on events, politics, business and more.
November 6, 2023
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter...
November 10, 2022
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid
November 8, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...
November 8, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...
August 3, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter...
February 28, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter...
August 12, 2021
Marketplace-ul de influenceri locali FameUP fondat de un antreprenor din Iași a obținut o finanțare seed de 2,5 milioane de euro, de la un grup de investitori din care fac parte fondul Early Game Ventures și fondatorul UiPath Daniel Dines.
June 30, 2021
STIRIPESURSE.RO vă prezintă actele normative adoptate de Guvern în ședința din 29 iunie 2021. Ședința a avut loc la scurt timp după ce parlamentarii au votat moțiunea de cenzură depusă de PSD împotriva cabinetului Florin Cîțu. Din cele 234 de voturi necesare, moțiunea a strâns doar 201. I. PROIECTE DE LEGE 1. PROIECT DE LEGE pentru modificarea şi completarea Anexei la Legea nr. 339/2005 privind regimul juridic al plantelor, substanțelor şi preparatelor stupefiante şi psihotr...
May 6, 2021
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosin...
February 25, 2021
Share this article Share this article SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the companys progress across its clinical and discovery pipeline and strength as it expands its operational structure and capabilities in preparation for potential commercialization in the United States. "Our commitment to patients with cancer...